Decamethonium

Summary

Decamethonium (CHEMBL1190) is an approved small-molecule nicotinic acetylcholine receptor agonist.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 258.49 Da · C16H38N2+2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1190
Name	Decamethonium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2968
ChEBI	CHEBI:41934
Molecular formula	C16H38N2+2
Molecular weight	258.49
InChIKey	MTCUAOILFDZKCO-UHFFFAOYSA-N

SMILES: C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C

IUPAC name: trimethyl-[10-(trimethylazaniumyl)decyl]azanium

ChEBI definition: A quaternary ammonium ion that is a depolarising muscle relaxant whose structure comprises a decane-1,10-diamine core in which each amino group carries three methyl substituents.

Pharmacological roles (ChEBI): muscle relaxant, nicotinic acetylcholine receptor agonist.

Also known as: Decamethonium cation, Decamethonium ion, Decamethonium, decamethonium, SID11111046, SID11111047, SID90341654, SID26756594, C-10, DECAMETHONIUM BROMIDE, DECAMETHONIUM

Parent form; salt/anhydrous children: CHEMBL1134

Patent coverage: 409 distinct patent families (1,139 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Prelamin-A/C, Ferritin light chain, Acetylcholinesterase, Histamine H3 receptor, Muscarinic acetylcholine receptor M1, Acetylcholinesterase, Nuclear factor NF-kappa-B p105 subunit, 3-hydroxyacyl-CoA dehydrogenase type-2.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NFKB1	6.2	Potency	631	nM	CHEMBL_ACT_3672709
NFKB1	6.2	Potency	631	nM	CHEMBL_ACT_4585990
HRH3	6.09	IC50	820	nM	CHEMBL_ACT_2141593
P21836	5.46	Ki	3500	nM	CHEMBL_ACT_2341268
ACHE	5.23	IC50	5900	nM	CHEMBL_ACT_2141588
LMNA	5.1	Potency	7943	nM	CHEMBL_ACT_3641652
P08482	5.05	Potency	8912	nM	CHEMBL_ACT_4857872
ACHE	5.04	AC50	9148	nM	CHEMBL_ACT_25142252

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).